Ind-Swift Laboratories Ltd Financials
Company Logo

Ind-Swift Laboratories Ltd Financial Statement

Ind-Swift Laboratories Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue41.60
Operating Expense34.99
Net Profit6.19
Net Profit Margin14.88
Earning Per Share1.05
EBIDTA6.61
Effective Tax RateTBA

Ind-Swift Laboratories Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual1,227.32
Operating Expenses Annual977.35
Operating Profit Annual681.87
Interest Annual51.10
Depreciation53.30
Net Profit Annual418.39
Tax Annual159.08

Ind-Swift Laboratories Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning9.96
Cash Flow from Operations-179.77
Cash Flow from Investing-104.32
Cash Flow from Financing699.86
Cash Flow at the End425.73

Ind-Swift Laboratories Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)23.88
PBIT Margin (%)19.53
PBT Margin (%)19.15
Net PROFIT Margin (%)34.09
Return On Networth / Equity (%)18.99
Return On Networth /Employed (%)20.55
Return On Assets (%)33.75
Total Debt / Equity (X)0.61
Asset Turnover Ratio (%)0.99

Ind-Swift Laboratories Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual5.32
Total Current Assets Annual545.54
Non Current Assets Annual559.25
Total Shareholders Funds Annual922.24
Total Assets Annual1,104.79

Ind-Swift Laboratories Ltd Earning Calls

EPS (INR)

Expected

0.16

Reported

0.16

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Sep 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Ind-Swift Laboratories Ltd has a market capitalization of 580.82 Cr. Value Research classifies it as a Small-Cap company.
Yes, Ind-Swift Laboratories Ltd is debt-free with a debt-to-equity ratio of 0.01.
In FY 2023 , Ind-Swift Laboratories Ltd recorded a total revenue of approximately 1,227.32 Cr marking a significant milestone in the company's financial performance.
Ind-Swift Laboratories Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and 0.1% annually, respectively..
Ind-Swift Laboratories Ltd's current PE ratio is 1.39.
Ind-Swift Laboratories Ltd's ROCE averaged 15.2% from the FY ending March 2022 to 2024, with a median of 12.9%. It peaked at 26.0% in March 2024, reflecting strong capital efficiency over the period..
Ind-Swift Laboratories Ltd's latest EBIT is Rs. 628.57 Cr, surpassing the average EBIT of Rs. 301.16 Cr over the 5 years..